Gene in Multiple Cancers
Article Sidebar
Published:
Feb 20, 2013
Main Article Content
Abstract
Genes are the determinants of individual appearance or phenotype. Several studies reveal the clinical association between genes and cancer. To study the genes and their relationship to cancer is the present focus in clinical oncology. In this specific brief review, the author would like to introduce a group of genes that are associated with multiple cancers.
Article Details
How to Cite
1.
Wiwanitkit V. Gene in Multiple Cancers. BKK Med J [Internet]. 2013 Feb. 20 [cited 2024 Nov. 22];5:71. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/218095
Issue
Section
Reviews Article
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
1. Graffi A. Observations on the theories of carcinogenesis.Arch Geschwulstforsch 1963;22:13-41.
2. Laerum OD. Current cancer theories and their scientific basis. Tidsskr Nor Laegeforen 1970;90:2067-70.
3. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002;23:381-7.
4. Borek C. Molecular mechanisms in cancer induction and prevention. Environ Health Perspect 1993;101:237-45.
5. Sutherland JE, Costa M. Epigenetics and the environment.Ann N Y Acad Sci 2003;983:151-60.
6. Weber W. Cancer epigenetics. Prog Mol Biol Transl Sci 2010;95:299-349.
7. McMillan SC. Carcinogenesis. Semin Oncol Nurs 1992;8:10-9.
8. Knudson AG Jr. Overview: genes that predispose to cancer. Mutat Res 1991;247:185-90.
9. Knudson AG Jr. The genetic predisposition to cancer.Birth Defects Orig Artic Ser 1989;25:15-27.
10. Werthamer S, Jabush M, Schulman J. Multiple primary malignancies. JAMA 1961;175:558-62.
11. Luciani A, Balducci L. Multiple primary malignancies.Semin Oncol 2004;31:264-73.
12. Capaldo GR, Kunschner AJ, Amin RM. Multiple primary neoplasms. Ovarian carcinoid tumor, mucinous cystade- noma of low malignant potential tumor of left ovary, and adenocarcinoma of the colon. Arch Pathol Lab Med 1996;120:393-6.
13. Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003;26:79-83.
14. Kobayashi T, Takahashi T, Tanaka T, et al. Multiple primary neoplasm--glioblastoma combined with cancer of other organs. No Shinkei Geka 1987;15:1011-7.
15. Klochikhin AL, Markov GI, Shilenkova VV. A case of a cure of synchronous multiple primary neoplasm of the laryngopharynx and stomach. Vestn Otorinolaringol 1997;1:56.
16. Sielanczyk A, Jakubowska D, Sierón A. Multiple primary neoplasm without family history-case report. Pol Merkur Lekarski 2004;16:255-7.
17. Schoenberg BS. Multiple primary malignant neoplasms. The Connecticut experience, 1935-1964. Recent Results Cancer Res 1977;58:1-173.
18. Ray P, Guinan P, Sharifi R, et al. Prostate cancer and the multiple primary malignant neoplasm syndrome. Prostate 1983;4:513-22.
19. Esposito ED, Bevilacqua L, Guadagno MT. Multiple primary malignant neoplasm in patients with laryngeal carcinoma. J Surg Oncol 2000;74:83-6.
20. Lynch HT, Guirgis HA, Lynch PM, et al. Familial cancer syndromes: a survey. Cancer 1977;39:1867-81.
21. Li FP. Familial cancer syndromes and clusters. Curr Probl Cancer 1990;14:73-114.
22. Den Otter W, Koten JW, Van der Vegt BJ, et al. Hereditary cancer and its clinical implications: a view. Anticancer Res 1990;10:489-95.
23. Seitz ML, Shenker IR,Leonidas JC, et al. Von Hippel-Lindau disease in an adolescent.Pediatrics 1987;79:632-7.
24. Neumann HP. The von Hippel-Lindau syndrome. Dtsch Med Wochenschr 1991;116:28-34.
25. Neumann HP. Von Hippel-Lindau syndrome. Nephrol Dial Transplant 1994;9:313-5.
26. Arjumand W, Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 2012;33:9-16.
27. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.
28. Audenet F, Yates DR, Cancel-Tassin G, et al. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 2012;109:1864-70.
29. Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 2010;4:58-73.
30. Monnier G, Mauduit G, Thivolet J. Cowden’s disease.Ann Dermatol Venereol 1985;112:169-77.
31. Salem OS, Steck WD. Cowden’s disease (multiple ham- artoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol 1983;8:686-96.
32. Civatte J, Laufer J, Delort J, et al. Cowden’s disease (multiple hamartoma syndrome). Review of the literature in connection with 1 case. Ann Med Interne (Paris) 1978;129:593-9.
33. Bardenstein DS, McLean IW, Nerney J, et al. Cowden’s disease. Ophthalmology 1988;95:1038-41.
34. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289-301.
35. Romano C, Schepis C. PTEN Gene: A Model for Genetic Diseases in Dermatology. Scientific World Journal 2012;2012:252457.
36. Eng C. Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carci- nogenesis. Ann N Y Acad Sci 2002;968:213-21.
37. Palmero EI, Achatz MI, Ashton-Prolla P, et al. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 2010;22:64-9.
38. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997;3:390-5.
39. Frebourg T. Li-Fraumeni syndrome. Bull Cancer 1997; 84:735-40.
40. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2:a001008.
41. Szymańska K, Hainaut P. TP53 and mutations in human cancer. Acta Biochim Pol 2003;50:231-8.
42. Bozzao C, Lastella P, Stella A. Anticipation in lynch syndrome: where we are where we go. Curr Genomics 2011;12:451-65.
43. Iwama T, Ishida H. Hereditary colorectal cancer; familial adenomatous polyposis, MUTYH associated polyposis and Lynch syndrome. Nihon Rinsho 2011; 69:59-64.
44. Gala M, Chung DC. Hereditary colon cancer syndromes.Semin Oncol 2011;38:490-9.
45. Gudgeon JM, Williams JL, Burt RW, et al. Lynch syndrome screening implementation: business analysis by a healthcare system. Am J Manag Care 2011;17:e288-300.
46. Weissman SM, Burt R, Church J, et al. Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. J Genet Couns 2011 Dec 14.
47. Mercader P. Muir-Torre syndrome. Adv Exp Med Biol 2010;685:186-95.
48. Kacerovská D, Kazakov DV, Cerná K, et al. Muir-Torre syndrome-a phenotypic variant of Lynch syndrome. Cesk Patol 2010;46:86-94.
49. Masuno M. Turcot syndrome. Ryoikibetsu Shokogun Shirizu 2001;(34 Pt 2):765-6.
50. Sunahara M, Nakagawara A. Turcot syndrome. Nihon Rinsho 2000;58:1484-9.
51. Shulman LP. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Obstet Gynecol Clin North Am 2010;37:109-33.
52. Plevová P, Novotný J, Petráková K, et al. Hereditary breast and ovarian cancer syndrome. Klin Onkol 2009;22:S8-11.
53. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107:159-62.
54. Beller U. Preconception counseling for the couple at risk preventing the hereditary breast and ovarian cancer syndrome. Int J Gynecol Cancer 2010;20:S29-30.
55. Wiwanitkit V. Cell, Gene and Molecular Therapy: New Concepts. New York: Nova Biomedical, 2009.
2. Laerum OD. Current cancer theories and their scientific basis. Tidsskr Nor Laegeforen 1970;90:2067-70.
3. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002;23:381-7.
4. Borek C. Molecular mechanisms in cancer induction and prevention. Environ Health Perspect 1993;101:237-45.
5. Sutherland JE, Costa M. Epigenetics and the environment.Ann N Y Acad Sci 2003;983:151-60.
6. Weber W. Cancer epigenetics. Prog Mol Biol Transl Sci 2010;95:299-349.
7. McMillan SC. Carcinogenesis. Semin Oncol Nurs 1992;8:10-9.
8. Knudson AG Jr. Overview: genes that predispose to cancer. Mutat Res 1991;247:185-90.
9. Knudson AG Jr. The genetic predisposition to cancer.Birth Defects Orig Artic Ser 1989;25:15-27.
10. Werthamer S, Jabush M, Schulman J. Multiple primary malignancies. JAMA 1961;175:558-62.
11. Luciani A, Balducci L. Multiple primary malignancies.Semin Oncol 2004;31:264-73.
12. Capaldo GR, Kunschner AJ, Amin RM. Multiple primary neoplasms. Ovarian carcinoid tumor, mucinous cystade- noma of low malignant potential tumor of left ovary, and adenocarcinoma of the colon. Arch Pathol Lab Med 1996;120:393-6.
13. Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003;26:79-83.
14. Kobayashi T, Takahashi T, Tanaka T, et al. Multiple primary neoplasm--glioblastoma combined with cancer of other organs. No Shinkei Geka 1987;15:1011-7.
15. Klochikhin AL, Markov GI, Shilenkova VV. A case of a cure of synchronous multiple primary neoplasm of the laryngopharynx and stomach. Vestn Otorinolaringol 1997;1:56.
16. Sielanczyk A, Jakubowska D, Sierón A. Multiple primary neoplasm without family history-case report. Pol Merkur Lekarski 2004;16:255-7.
17. Schoenberg BS. Multiple primary malignant neoplasms. The Connecticut experience, 1935-1964. Recent Results Cancer Res 1977;58:1-173.
18. Ray P, Guinan P, Sharifi R, et al. Prostate cancer and the multiple primary malignant neoplasm syndrome. Prostate 1983;4:513-22.
19. Esposito ED, Bevilacqua L, Guadagno MT. Multiple primary malignant neoplasm in patients with laryngeal carcinoma. J Surg Oncol 2000;74:83-6.
20. Lynch HT, Guirgis HA, Lynch PM, et al. Familial cancer syndromes: a survey. Cancer 1977;39:1867-81.
21. Li FP. Familial cancer syndromes and clusters. Curr Probl Cancer 1990;14:73-114.
22. Den Otter W, Koten JW, Van der Vegt BJ, et al. Hereditary cancer and its clinical implications: a view. Anticancer Res 1990;10:489-95.
23. Seitz ML, Shenker IR,Leonidas JC, et al. Von Hippel-Lindau disease in an adolescent.Pediatrics 1987;79:632-7.
24. Neumann HP. The von Hippel-Lindau syndrome. Dtsch Med Wochenschr 1991;116:28-34.
25. Neumann HP. Von Hippel-Lindau syndrome. Nephrol Dial Transplant 1994;9:313-5.
26. Arjumand W, Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 2012;33:9-16.
27. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.
28. Audenet F, Yates DR, Cancel-Tassin G, et al. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 2012;109:1864-70.
29. Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 2010;4:58-73.
30. Monnier G, Mauduit G, Thivolet J. Cowden’s disease.Ann Dermatol Venereol 1985;112:169-77.
31. Salem OS, Steck WD. Cowden’s disease (multiple ham- artoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol 1983;8:686-96.
32. Civatte J, Laufer J, Delort J, et al. Cowden’s disease (multiple hamartoma syndrome). Review of the literature in connection with 1 case. Ann Med Interne (Paris) 1978;129:593-9.
33. Bardenstein DS, McLean IW, Nerney J, et al. Cowden’s disease. Ophthalmology 1988;95:1038-41.
34. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289-301.
35. Romano C, Schepis C. PTEN Gene: A Model for Genetic Diseases in Dermatology. Scientific World Journal 2012;2012:252457.
36. Eng C. Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carci- nogenesis. Ann N Y Acad Sci 2002;968:213-21.
37. Palmero EI, Achatz MI, Ashton-Prolla P, et al. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 2010;22:64-9.
38. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997;3:390-5.
39. Frebourg T. Li-Fraumeni syndrome. Bull Cancer 1997; 84:735-40.
40. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2:a001008.
41. Szymańska K, Hainaut P. TP53 and mutations in human cancer. Acta Biochim Pol 2003;50:231-8.
42. Bozzao C, Lastella P, Stella A. Anticipation in lynch syndrome: where we are where we go. Curr Genomics 2011;12:451-65.
43. Iwama T, Ishida H. Hereditary colorectal cancer; familial adenomatous polyposis, MUTYH associated polyposis and Lynch syndrome. Nihon Rinsho 2011; 69:59-64.
44. Gala M, Chung DC. Hereditary colon cancer syndromes.Semin Oncol 2011;38:490-9.
45. Gudgeon JM, Williams JL, Burt RW, et al. Lynch syndrome screening implementation: business analysis by a healthcare system. Am J Manag Care 2011;17:e288-300.
46. Weissman SM, Burt R, Church J, et al. Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. J Genet Couns 2011 Dec 14.
47. Mercader P. Muir-Torre syndrome. Adv Exp Med Biol 2010;685:186-95.
48. Kacerovská D, Kazakov DV, Cerná K, et al. Muir-Torre syndrome-a phenotypic variant of Lynch syndrome. Cesk Patol 2010;46:86-94.
49. Masuno M. Turcot syndrome. Ryoikibetsu Shokogun Shirizu 2001;(34 Pt 2):765-6.
50. Sunahara M, Nakagawara A. Turcot syndrome. Nihon Rinsho 2000;58:1484-9.
51. Shulman LP. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Obstet Gynecol Clin North Am 2010;37:109-33.
52. Plevová P, Novotný J, Petráková K, et al. Hereditary breast and ovarian cancer syndrome. Klin Onkol 2009;22:S8-11.
53. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107:159-62.
54. Beller U. Preconception counseling for the couple at risk preventing the hereditary breast and ovarian cancer syndrome. Int J Gynecol Cancer 2010;20:S29-30.
55. Wiwanitkit V. Cell, Gene and Molecular Therapy: New Concepts. New York: Nova Biomedical, 2009.